State Key Laboratory of Bioelectronics (Chien-Shiung Wu Lab), School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
Department of Hepatic-Biliary-Pancreatic Center, Zhongda Hospital, Southeast University, Nanjing, China.
J Mater Chem B. 2019 Sep 11;7(35):5336-5344. doi: 10.1039/c9tb01070j.
Nanomaterials have made great breakthroughs in drug delivery. However, in previous studies, nanomaterials have been mostly used as vehicles to transport drugs into tumors. Herein, we first found that the in situ biosynthesized gold nanoparticles (Au NCs) can inhibit cancer development via the inhibition of some signaling pathways. Classical cell phenotypic assay tests and orthotropic liver tumor model both showed that the in situ biosynthesized Au NCs could inhibit tumor development. With the help of the RNA-seq analysis, we found that the in situ biosynthesized Au NCs could significantly inhibit the PI3K-AKT signaling pathway, thus effectively impeding tumor development. This facile and effective tumor targeting theranostics in vivo can effectively cure cancers in future clinical applications.
纳米材料在药物输送方面取得了重大突破。然而，在以前的研究中，纳米材料大多被用作将药物输送到肿瘤的载体。在此，我们首次发现原位生物合成的金纳米颗粒（AuNCs）可以通过抑制某些信号通路来抑制癌症的发展。经典的细胞表型检测试验和原位肝肿瘤模型均表明，原位生物合成的 AuNCs 可以抑制肿瘤的发展。借助 RNA-seq 分析，我们发现原位生物合成的 AuNCs 可以显著抑制 PI3K-AKT 信号通路，从而有效阻止肿瘤的发展。这种简便有效的体内肿瘤靶向治疗可以在未来的临床应用中有效地治愈癌症。
